Advanced Biopharmaceutical Facility, Holly Springs, NC – United States 

Countries
United States (Holly Springs, North Carolina)

Companies

FUJIFILM Diosynth Biotechnologies – Owner / Developer
FUJIFILM Holdings Corporation – Parent Company
DPR Construction – General Contractor (life sciences expertise)
Jacobs Engineering Group – Engineering / Project Support
Multiple specialized subcontractors (cleanroom, piping, process systems)

Budget

Initial Investment: ~$2 billion
Expansion Investment: +$1.2 billion
Total Estimated Investment: ~$3.2+ billion

Scope

Construction of one of North America’s largest end-to-end biopharmaceutical manufacturing campuses
Development of a ~1 million sq. ft. large-scale facility with expansion capability
Multiple manufacturing suites for drug substance and drug product production
Integration of:
Cell culture production units
Fill-finish manufacturing
Packaging and distribution systems
Supporting infrastructure: utilities, cleanrooms, laboratories, warehousing, and logistics systems

Technologies

Large-scale cell culture bioreactors (20,000 L capacity units)
Advanced biologics manufacturing systems (monoclonal antibodies, vaccines, gene therapies)
cGMP (current Good Manufacturing Practice) compliant cleanroom environments
Automated fill-finish and packaging systems
High-purity piping and process systems (hygienic piping networks)
Sustainable design and energy-efficient infrastructure

Project Management Authority / Implementing Agency

FUJIFILM Diosynth Biotechnologies – Project Owner & Operator
North Carolina State Government & Economic Development Agencies – Support and incentives
Wake County & Town of Holly Springs – Local implementation support

Timeline

Announcement & Planning: 2021
Construction Start: 2021
Expansion Announcement: 2024
Initial Completion / Opening: ~2025
Ongoing Expansion: Mid-2020s onward

Contractor

DPR Construction
Subcontractor

Fluor Corporation

Purpose
The Advanced Biopharmaceutical Facility in Holly Springs was developed to establish a global hub for large-scale biologics manufacturing, enabling the production of life-saving medicines such as vaccines, monoclonal antibodies, and advanced therapies. Designed as a Contract Development and Manufacturing Organization (CDMO), the facility supports pharmaceutical companies worldwide by providing end-to-end services—from research and development to commercial-scale production. It also strengthens the United States’ domestic pharmaceutical supply chain, accelerates drug delivery to patients, and positions North Carolina as a leading center for life sciences innovation and biomanufacturing.